Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) and Deputy Programme Director for High Consequence Infectious Diseases, NHS England, is appointed MBE for services to Clinical Research. Dr Dunning led clinical trials during the terrible Ebola epidemic in West Africa.

Jake Dunning
Dr Jake Dunning, Honorary Visiting Research Fellow at the Centre for Tropical Medicine and Global Health, has been awarded an MBE in the New Year's Honours list. The award recognises his services to clinical research, particularly his contributions to Ebola research efforts. Jake joined the Epidemic diseases Research Group Oxford (ERGO) in October 2014, as part of the RAPIDE trial team studying potential treatments for Ebola virus disease in West Africa. The trials, led by Prof Peter Horby, evaluated two candidate drugs at Ebola treatment centres in Liberia and Sierra Leone. Jake was the Field Lead for the trials, based in West Africa, and worked with over 40 researchers from 10 countries, including doctors and nurses from the affected countries.
Following completion of the trials in 2015, Jake moved to a new full time post as Consultant in Infectious Diseases at the National Infection Service, Public Health England. However, he continues to work with ERGO on preparedness and response activities for outbreak research. Additionally, Jake is the NHS England Deputy Programme Director for High Consequence Infectious Diseases, which includes diseases such as viral haemorrhagic fever, avian influenza, and pneumonic plague. He also practises clinical infectious diseases at the Royal Free Hospital, London. Along with other trial team members, Jake received a British Government Ebola Service Medal in 2015, and his international colleagues were recognised with the award of Oxford Ebola service medals.
On receiving his award, Jake said "I am very grateful to have received this honour, mindful that I was part of a brilliant and dedicated team. Without the extraordinary support of colleagues in the field and in Oxford, these unique and very challenging trials would not have happened. We are now applying the skills and lessons learned to improving outbreak preparedness, response and research activities for high consequence infections, both overseas and in the UK. I am indebted to Peter Horby and the Centre, for having provided me with such an amazing opportunity.

Read more »

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

UK National Health Service begins rollout of Oxford coronavirus vaccine

@Oxford General

The first patients are being vaccinated as part of the UK’s rollout of the Oxford / AstraZeneca coronavirus vaccine, ChAdOx1 nCoV-19, at the Oxford University NHS Hospitals Trust. The Oxford AstraZeneca vaccinations will be delivered at a small number of hospitals for the first few days for surveillance purposes, as is standard practice, before the bulk of supplies are sent to hundreds of GP-led services later in the week.

Susie Dunachie awarded flagship NIHR career development award

@Oxford Awards & Appointments

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

AfOx receives the Wellcome Institutional Strategic Support Fund to launch the Africa Health Innovation Platform

@Oxford

AfOx in collaboration with partners across the UK and Africa has received a Wellcome Institutional Strategic Support Fund to establish an Africa Health Innovation Platform. The multi-disciplinary platform will support African innovators who develop new solutions to Africa’s health challenges, bringing together researchers, entrepreneurs, investors, technologists, policymakers, and change leaders to develop new approaches towards prevention, early detection and treatment of diseases.